

# Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026

<https://marketpublishers.com/r/EFE290639D36EN.html>

Date: February 2021

Pages: 187

Price: US\$ 3,500.00 (Single User License)

ID: EFE290639D36EN

## Abstracts

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Europe Cell and Gene Therapy Market Report

The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 2021–2026.

The global cell and gene therapy market is observing significant mergers and acquisition activities, product sales, and new market authorizations. In 2026, the market is expected to grow almost four times more than the current value, with new product approvals expected annually. Although initial product approvals have been for relatively small patient groups, the significant pipeline of cell & gene therapy studies for diseases such as hemophilia and various forms of blindness will significantly expand. In addition, the Europe market is witnessing steady growth due to the increased availability of funds from several public and private institutes. There is increased support from regulatory bodies for product approvals and fast-track product designations, which encourage vendors to manufacture products at a fast rate. Moreover, with over 237 regenerative medicines companies headquartered in Europe, the region is seen as the favorite destination for cell and gene therapy manufacturing.

The following factors are likely to contribute to the growth of the Europe cell and gene therapy market during the forecast period:

CMOs Offering Vector Manufacturing Services for Cell and Gene Therapy Companies

Robust Cell & Gene Therapies in the Pipeline

## Increase in Strategic Acquisitions

## Regulatory Support for Cell and Gene Therapy Products

The study considers the present scenario of the Europe cell and gene therapy market and its market dynamics for the period 2020-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

## Europe Cell and Gene Therapy Market Segmentation

The Europe cell and gene therapy market research report includes a detailed segmentation by product, end-user, application, geography. A high potential to treat several chronic diseases, which cannot be effectively treated/cured through conventional methods otherwise, is propelling the growth of gene therapies. Gene therapies are regarded as a potential revolution in the health sciences and pharmaceutical fields. The number of clinical trials investigating gene therapies is increasing in Europe, despite the limited number of products that have successfully reached the market. However, gene therapies show slow progress and promising prospect in terms of treatments. High support from regulatory bodies to commercialize these products and make them affordable to patients is another important factor contributing the market growth.

Delivering cell and gene therapies requires specialized facilities, capabilities, and clinician skills. Therefore, manufacturers are working in tandem with chosen treatment centers (hospitals) to establish the protocols and procedures necessary to receive the product and therapies. While cell therapies represent a paradigm shift in the treatment of several incurable, chronic diseases, with durable responses and long-term disease control measures, hospitals appear an ideal location to carry out these procedures. Hospitals are growing at a significant rate due to the increasing target population in Europe. Tier-I hospitals are proving to be sought-after network partners for cell and gene therapy developers. They tend to be in major population centers, have adequate financial and personnel resources, and value the prestige that comes with being the first movers in an innovative treatment area.

Oncology accounted for a share of over 30% in 2020. While cancer treatments have

evolved and undergone massive developments in recent years, it continues to be one of the deadliest diseases confronted by humans. Traditional cancer therapies have a curative effect in the short term; however, they have side effects, thereby decreasing the patient's quality of life. Cell and gene therapies for certain types of cancers have been promising results. The chimeric antigen receptor- (CAR-) T cell therapy is one of the most recent innovative immunotherapies and is rapidly evolving. CAR-T cell therapies are developing rapidly, and many clinical trials have been established on a global scale, which has high commercial potential for the treatment of cancer. Immunotherapies based on CAR-T cells go one step further, engineering the T cells themselves to enhance the natural immune response against a specific tumor antigen. CAR-T clinical trials have shown high remission rates, up to 94%, in severe forms of blood cancer, thereby increasing the market growth.

## **Product**

Cell Therapies

Gene Therapies

## **End-user**

Hospitals

Cancer Care Centers

Wound Care Centers

Others

## **Application**

Oncology

Dermatology

Musculoskeletal

Others

## **INSIGHTS BY GEOGRAPHY**

Germany, France, the UK, Italy, and Spain play a significant role in the Europe cell and gene therapy market. Clinical trials and the number of manufacturing facilities are increasing slowly in the European region. The region has become a major R&D destination for several vendors as the funding for cell & gene therapies is increasing. Europe has supported collaborative efforts in gene transfer and gene therapy research. In addition, the target patient population is increasing across Europe; there were an estimated 3.9 million new cases of cancer and 1.9 million cancer deaths in Europe in 2018. In addition, the prevalence surveys in the UK and Denmark indicate that there are 3–4 people with one or more wounds per 1,000 people. Favorable government support in terms of product approvals, reimbursement and coverage, and high R&D funding to academic institutes that are involved in the development of cell and gene therapies are expected to boosting the market in Europe.

### **Geography**

Europe

UK

Germany

France

Italy

Spain

Switzerland

Netherlands

## **INSIGHTS BY VENDORS**

Novartis, Spark Therapeutics, Amgen, Gilead Sciences, and Organogenesis are the leading players in the Europe cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players on account of the presence of a large pool of target patient population with chronic diseases such as cancer, wound disorders, diabetic foot ulcer, CVDs, and other genetic disorders. Recent approvals have prompted an unprecedented expansion among vendors. While a few vendors are opting for in-house production of cell and gene therapies, a substantial number of vendors are preferring third-party service providers, including CMOs.

### **Prominent Vendors**

Novartis

Spark Therapeutics

Amgen

Gilead Sciences

Organogenesis

### **Other Prominent Vendors**

APAC Biotech

AVITA Medical

bluebird bio

CHIESI Farmaceutici

CollPlant

CO.DON

Human Stem Cells Institute PJSC (HSCI)

Medipost

NuVasive

Nipro

Orchard Therapeutics

RMS Regenerative Medical System

Orthocell

Osiris Therapeutics

Sibino GeneTech

Shanghai Sunway Biotech

Takeda Pharmaceutical Company

Terumo

Vericel

### **Emerging Investigational Vendors In Europe**

Adaptimmune Therapeutics

AgenTus Therapeutics

Autolus

Cellecits

Celyad

CombiGene

EUKAR?S

Freeline Therapeutics

Innoskel

PsiOxus Therapeutics Ltd

SparingVision

uniQure

## **KEY QUESTIONS ANSWERED**

1. What is the Europe cell and gene therapy market size and growth rate during the forecast period?
2. What are the factors driving the demand for CAR-T therapy in the European region?
3. How are strategic acquisitions aiding in market growth of cell and gene therapy products?
4. Which segments are expected to generate the highest revenues during the forecast period?
5. Who are the leading vendors in the European cell and gene therapy market?

## Contents

### **1 RESEARCH METHODOLOGY**

### **2 RESEARCH OBJECTIVES**

### **3 RESEARCH PROCESS**

### **4 SCOPE & COVERAGE**

#### 4.1 Market Definition

##### 4.1.1 Inclusions

##### 4.1.2 Exclusions

#### 4.2 Base Year

#### 4.3 Scope of The Study

##### 4.3.1 Market Segmentation by Product

##### 4.3.2 Market Segmentation by Application

##### 4.3.3 Market Segmentation by End-Users

##### 4.3.4 Market Segmentation by Geography

### **5 REPORT ASSUMPTIONS & CAVEATS**

#### 5.1 Key Caveats

#### 5.2 Currency Conversion

#### 5.3 Market Derivation

### **6 MARKET AT A GLANCE**

### **7 INTRODUCTION**

#### 7.1 Overview

### **8 MARKET OPPORTUNITIES & TRENDS**

#### 8.1 CMO Offering Vector-Manufacturing Services

#### 8.2 Robust Cell & Gene Therapy Pipeline

#### 8.3 Increase In Strategic Acquisitions

### **9 MARKET GROWTH ENABLERS**



- 9.1 Regulatory Support For Cell And Gene Therapy Market
- 9.2 Increasing Demand For CAR-T Therapy In Europe
- 9.3 Product Launches And Approvals

## **10 MARKET RESTRAINTS**

- 10.1 COVID-19 Impact on Cell And Gene Therapy Products
- 10.2 Increasing Pricing Pressure for Cell & Gene Therapy Products
- 10.3 Limitations of Gene Therapy Products

## **11 MARKET LANDSCAPE**

- 11.1 Market Overview
- 11.2 Market Size & Forecast
- 11.3 Five Forces Analysis
  - 11.3.1 Threat of New Entrants
  - 11.3.2 Bargaining Power of Suppliers
  - 11.3.3 Bargaining Power of Buyers
  - 11.3.4 Threat of Substitutes
  - 11.3.5 Competitive Rivalry

## **12 PRODUCT**

- 12.1 Market Snapshot & Growth Engine
- 12.2 Market Overview
- 12.3 Cell Therapy
  - 12.3.1 Market Overview
  - 12.3.2 Market Size & Forecast
- 12.4 Gene Therapy
  - 12.4.1 Market Overview
  - 12.4.2 Market Size & Forecast

## **13 APPLICATION**

- 13.1 Market Snapshot & Growth Engine
- 13.2 Market Overview
- 13.3 Oncology
  - 13.3.1 Market Overview

- 13.3.2 Market Size & Forecast
- 13.4 Dermatology
  - 13.4.1 Market Overview
  - 13.4.2 Market Size & Forecast
- 13.5 Musculoskeletal
  - 13.5.1 Market Overview
  - 13.5.2 Market Size & Forecast
- 13.6 Others
  - 13.6.1 Market Overview
  - 13.6.2 Market Size & Forecast

## **14 END-USERS**

- 14.1 Market Snapshot & Growth Engine
- 14.2 Market Overview
- 14.3 Hospitals
  - 14.3.1 Market Overview
  - 14.3.2 Market Size & Forecast
- 14.4 Cancer Care Centers
  - 14.4.1 Market Overview
  - 14.4.2 Market Size & Forecast
- 14.5 Wound Care Centers
  - 14.5.1 Market Overview
  - 14.5.2 Market Size & Forecast
- 14.6 Others
  - 14.6.1 Market Overview
  - 14.6.2 Market Size & Forecast

## **15 GEOGRAPHY**

- 15.1 Market Snapshot & Growth Engine
- 15.2 Geographic Overview

## **16 WESTERN EUROPE**

- 16.1 Market Overview
- 16.2 Market Size & Forecast

## **17 REST OF EUROPE**

17.1 Market Overview

17.2 Market Size & Forecast

## **18 KEY COUNTRIES**

18.1 Germany: Market Size & Forecast

18.2 France: Market Size & Forecast

18.3 UK: Market Size & Forecast

18.4 Italy: Market Size & Forecast

18.5 Spain: Market Size & Forecast

18.6 Switzerland: Market Size & Forecast

18.7 The Netherlands: Market Size & Forecast

## **19 COMPETITIVE LANDSCAPE**

19.1 Competition Overview

19.2 Market Share Analysis

19.2.1 Novartis

19.2.2 Spark Therapeutics

19.2.3 Amgen

19.2.4 Gilead Sciences

19.2.5 Organogenesis

## **20 KEY COMPANY PROFILES**

20.1 Novartis

20.1.1 Business Overview

20.1.2 Product Offerings

20.1.3 Key Strategies

20.1.4 Key Strengths

20.1.5 Key Opportunities

20.2 Spark Therapeutics

20.2.1 Business Overview

20.2.2 Product Offerings

20.2.3 Key Strategies

20.2.4 Key Strengths

20.2.5 Key Opportunities

20.3 AMGEN

- 20.3.1 Business Overview
- 20.3.2 Product Offerings
- 20.3.3 Key Strategies
- 20.3.4 Key Strengths
- 20.3.5 Key Opportunities
- 20.4 Gilead Sciences
  - 20.4.1 Business Overview
  - 20.4.2 Product Offerings
  - 20.4.3 Key Strategies
  - 20.4.4 Key Strengths
  - 20.4.5 Key Opportunities
- 20.5 Organogenesis
  - 20.5.1 Business Overview
  - 20.5.2 Product Offerings
  - 20.5.3 Key Strategies
  - 20.5.4 Key Strengths
  - 20.5.5 Key Opportunities

## **21 OTHER PROMINENT VENDORS**

- 21.1 APAC Biotech
  - 21.1.1 Business Overview
  - 21.1.2 Product Offerings
- 21.2 Avita Medical
  - 21.2.1 Business Overview
  - 21.2.2 Product Offerings
- 21.3 bluebird bio
  - 21.3.1 Business Overview
  - 21.3.2 Product Offerings
- 21.4 Chiesi Farmaceutici
  - 21.4.1 Business Overview
  - 21.4.2 Product Offerings
- 21.5 Collplant
  - 21.5.1 Business Overview
  - 21.5.2 Product Offerings
- 21.6 CO.DON
  - 21.6.1 Business Overview
  - 21.6.2 Product Offerings
- 21.7 Human Stem Cell Institute

- 21.7.1 Business Overview
- 21.7.2 Product Offerings
- 21.8 Medipost
  - 21.8.1 Business Overview
  - 21.8.2 Product Offerings
- 21.9 Nuvasive
  - 21.9.1 Business Overview
  - 21.9.2 Product Offerings
- 21.10 Nipro
  - 21.10.1 Business Overview
  - 21.10.2 Product Offerings
- 21.11 Orchard Therapeutics
  - 21.11.1 Business Overview
  - 21.11.2 Product Offerings
- 21.12 RMS Regenerative Medical System
  - 21.12.1 Business Overview
  - 21.12.2 Product Offerings
- 21.13 Orthocell
  - 21.13.1 Business Overview
  - 21.13.2 Product Offerings
- 21.14 Osiris Therapeutics
  - 21.14.1 Business Overview
  - 21.14.2 Product Offerings
- 21.15 Sibiono Genetech
  - 21.15.1 Business Overview
  - 21.15.2 Product Offerings
- 21.16 Shanghai Sunway Biotech
  - 21.16.1 Business Overview
  - 21.16.2 Product Offerings
- 21.17 Takeda Pharmaceutical Company
  - 21.17.1 Business Overview
  - 21.17.2 Product Offerings
- 21.18 Terumo
  - 21.18.1 Business Overview
  - 21.18.2 Product Offerings
- 21.19 Vericel
  - 21.19.1 Business Overview
  - 21.19.2 Product Offerings

## **22 EMERGING INVESTIGATIONAL VENDORS IN EUROPE**

### 22.1 Adaptimmune Therapeutics

#### 22.1.1 Business Overview

### 22.2 AgenTus

#### 22.2.1 Business Overview

### 22.3 Autolus

#### 22.3.1 Business Overview

### 22.4 Cellectis

#### 22.4.1 Business Overview

### 22.5 Celyad

#### 22.5.1 Business Overview

### 22.6 CombiGene

#### 22.6.1 Business Overview

### 22.7 EUKAR?S

#### 22.7.1 Business Overview

### 22.8 Freeline Therapeutics

#### 22.8.1 Business Overview

### 22.9 Innoskel

#### 22.9.1 Business Overview

### 22.10 PSIOXUS Therapeutics

#### 22.10.1 Business Overview

### 22.11 Sparing Vision

#### 22.11.1 Business Overview

### 22.12 Uniqure

#### 22.12.1 Business Overview

## **23 REPORT SUMMARY**

### 23.1 Key Takeaways

### 23.2 Strategic Recommendations

## **24 QUANTITATIVE SUMMARY**

### 24.1 Market by Geography

### 24.2 Market by Product

### 24.3 Market by End-User

### 24.4 Market by Application

## **25 APPENDIX**

### 25.1 Abbreviations

## List Of Exhibits

### LIST OF EXHIBITS

- Exhibit 1 Cell and Gene Therapy Market in Europe: Segmentation
- Exhibit 2 Market Size Calculation Approach 2020
- Exhibit 3 ATMPs in Development in Europe 2019
- Exhibit 4 Impact of CMOs Offering Vector-Manufacturing Services
- Exhibit 5 Cell & Gene Therapy Supply Chain
- Exhibit 6 Impact of Robust Cell & Gene Therapy Pipeline
- Exhibit 7 Impact of Increase in Strategic Acquisitions
- Exhibit 8 Impact of Regulatory Support for Cell and Gene Therapy Market
- Exhibit 9 Regulatory Pathway for Market Approval in Europe
- Exhibit 10 Impact of Increasing Demand for CAR-T Therapy in Europe
- Exhibit 11 Impact of Product Launches and Approvals
- Exhibit 12 Impact of Covid-19 on Cell and Gene Therapy Products
- Exhibit 13 Gene Therapy Trials Disrupted by Covid-19
- Exhibit 14 Impact of Increasing Pricing Pressure for the Cell and Gene Therapy Products
- Exhibit 15 Impact of Limitations of Gene Therapy Products
- Exhibit 16 Cell & Gene Therapy Expenditure by European Companies 2019 (\$ billion)
- Exhibit 17 Recent Development & Commercialization of Cell & Gene Therapy Products in Europe
- Exhibit 18 Cell & Gene Therapy Market in Europe by Product 2020 & 2026 (% share)
- Exhibit 19 Cell & Gene Therapy Market in Europe by Application 2020 & 2026 (% share)
- Exhibit 20 Cell & Gene Therapy Market in Europe by End-Users 2020 & 2026 Percentage Share Comparison
- Exhibit 21 Cell & Gene Therapy Market in Europe by Geography: 2020 & 2026 (% share)
- Exhibit 22 Cell & Gene Therapy Market in Europe 2020–2026 (\$ million)
- Exhibit 23 Five Forces Analysis 2020
- Exhibit 24 Incremental Growth by Product 2020 & 2026
- Exhibit 25 Europe Cell & Gene Therapy Market Segmentation by Product
- Exhibit 26 Europe Cell & Gene Therapy Market by Product: Incremental Growth
- Exhibit 27 Europe Cell & Gene Therapy Market by Product: Absolute Growth
- Exhibit 28 CAR-T Cell Treated Patients Registered in EMBT Registry
- Exhibit 29 Cell & Gene Therapy Market by Cell Therapy in Europe: Incremental Growth & Absolute Growth Comparison
- Exhibit 30 Cell & Gene Therapy Market in Europe by Cell Therapy Product 2020–2026



(\$ million)

Exhibit 31 Cell & Gene Therapy Market in Europe by Gene Therapy: Incremental Growth & Absolute Growth Comparison

Exhibit 32 Cell & Gene Therapy Market in Europe by Gene Therapy Product 2020–2026 (\$ million)

Exhibit 33 Incremental Growth by Application 2020 & 2026

Exhibit 34 Europe Cell & Gene Therapy Market Segmentation by Application

Exhibit 35 Cell & Gene Therapy Market in Europe by Application: Incremental Growth

Exhibit 36 Europe Cell & Gene Therapy Market by Application: Absolute Growth

Exhibit 37 Europe Cell & Gene Therapy Market by Oncology: Incremental Growth & Absolute Growth Comparison

Exhibit 38 Europe Cell & Gene Therapy Market by Oncology 2020–2026 (\$ million)

Exhibit 39 Europe Cell & Gene Therapy Market by Dermatology: Incremental Growth & Absolute Growth Comparison

Exhibit 40 Cell & Gene Therapy Market in Europe by Dermatology 2020–2026 (\$ million)

Exhibit 41 Europe Cell & Gene Therapy Market by Musculoskeletal: Incremental Growth & Absolute Growth Comparison

Exhibit 42 Cell & Gene Therapy Market in Europe by Musculoskeletal 2020–2026 (\$ million)

Exhibit 43 Cell & Gene Therapy Market in Europe by Others: Incremental Growth & Absolute Growth Comparison

Exhibit 44 Cell & Gene Therapy Market in Europe by Others 2020–2026 (\$ million)

Exhibit 45 Incremental Growth by End-Users 2020 & 2026

Exhibit 46 Europe Cell & Gene Therapy Market Segmentation by End-user

Exhibit 47 Cell & Gene Therapy Market in Europe by End-User: Incremental Growth

Exhibit 48 Cell & Gene Therapy Market in Europe by End-User: Absolute Growth

Exhibit 49 Cell & Gene Therapy Market in Europe by Hospitals: Incremental Growth & Absolute Growth Comparison

Exhibit 50 Cell & Gene Therapy Market in Europe by Hospitals 2020–2026 (\$ million)

Exhibit 51 Cell & Gene Therapy Market in Europe by Cancer Care Centers: Incremental Growth & Absolute Growth Comparison

Exhibit 52 Cell & Gene Therapy Market by Cancer Care Centers in Europe 2020–2026 (\$ million)

Exhibit 53 Cell & Gene Therapy Market in Europe by Wound Care Centers: Incremental Growth & Absolute Growth Comparison

Exhibit 54 Cell & Gene Therapy Market by Wound Care Clinics in Europe 2020–2026 (\$ million)

Exhibit 55 Cell & Gene Therapy Market in Europe by Others: Incremental Growth &

## Absolute Growth Comparison

Exhibit 56 Cell & Gene Therapy Market in Europe by Others 2020–2026 (\$ million)

Exhibit 57 Incremental Growth by Geography 2020 & 2026

Exhibit 58 Europe Cell & Gene Therapy Market Segmentation by Geography

Exhibit 59 Cell & Gene Therapy Market in Europe by Geography: Incremental Growth

Exhibit 60 Cell & Gene Therapy Market in Europe by Geography: Absolute Growth

Exhibit 61 Global Audience of European Society of Cell & Gene Therapy

Exhibit 62 Main Contribution for European Society of Cell and Gene Therapy

Exhibit 63 Healthcare Expenditure of Western European Countries Relative to their GDP

Exhibit 64 Cell & Gene Therapy Market in Western Europe: Incremental Growth & Absolute Growth Comparison

Exhibit 65 Cell & Gene Therapy Market in Western Europe 2020–2026 (\$ million)

Exhibit 66 Healthcare Expenditure of Eastern European Countries Relative to their GDP

Exhibit 67 Cell & Gene Therapy Market in Rest of Europe: Incremental Growth & Absolute Growth Comparison

Exhibit 68 Cell & Gene Therapy Market in Rest of Europe 2020–2026 (\$ million)

Exhibit 69 Incremental Growth in Key Countries 2020 & 2026

Exhibit 70 Cell and Gene Therapy Market in Germany 2020–2026 (\$ million)

Exhibit 71 Cell and Gene Therapy Market in France 2020–2026 (\$ million)

Exhibit 72 Cell and Gene Therapy Market in UK 2020–2026 (\$ million)

Exhibit 73 Cell and Gene Therapy Market in Italy 2020–2026 (\$ million)

Exhibit 74 Cell and Gene Therapy Market in Spain 2020–2026 (\$ million)

Exhibit 75 Cell and Gene Therapy Market in Switzerland 2020–2026 (\$ million)

Exhibit 76 Cell and Gene Therapy Market in Netherlands 2020–2026 (\$ million)

Exhibit 77 Novartis Revenue 2017-2019 (\$ billion)

Exhibit 78 Novartis Segment Revenue Share 2019

Exhibit 79 Novartis: Regional Revenue Breakup 2019 (%)

Exhibit 80 Amgen Revenue 2019 - 2017 (\$ billion)

Exhibit 81 Amgen: R&D Expenditure 2019 - 2017 (\$ billion)

Exhibit 82 Gilead Sciences Revenue 2017–2019 (\$ billion)

Exhibit 83 Gilead Sciences Research & Development Expenses 2017–2019 (\$ billion)

Exhibit 84 Organogenesis Revenue 2018–2019 (\$ million)

## List Of Tables

### LIST OF TABLES

Table 1 Key Caveats

Table 2 Currency Conversion 2013?2020

Table 3 Comparison of Conventional Therapy Versus ATMPs

Table 4 CMO Vector Manufacturers in Europe

Table 5 Gene Therapies in Significant Stages of Clinical Pipeline

Table 6 Recent Strategic Acquisitions in Europe Cell & Gene Therapy Market

Table 7 Product Approvals & Launches

Table 8 Major Cell & Gene Therapy Products Anticipated Near-Term Approvals in Europe

Table 9 Major Cell & Gene Therapy Products Anticipated Near-Term Approvals in Europe

Table 10 Major Cell & Gene Therapy Products Approved in Europe

Table 11 Gene Therapy Product Approved BY EMA

Table 12 Oncology Application Based Cell & Gene Therapy Products

Table 13 Oncology Application Based Cell & Gene Therapy Products

Table 14 Oncology Application Based Cell & Gene Therapy Products

Table 15 Other Application Based Cell & Gene Therapy Products

Table 16 Novartis: Major Product Offerings

Table 17 Spark Therapeutics: Major Product Offerings

Table 18 Amgen: Major Product Offerings

Table 19 Gilead Sciences: Major Product Offerings

Table 20 Organogenesis: Major Product Offerings

Table 21 APAC Biotech: Major Product Offerings

Table 22 AVITA MEDICAL: Major Product Offerings

Table 23 bluebird bio: Major Product Offerings

Table 24 CHIESI Farmaceutici: Major Product Offerings

Table 25 COLLPLANT: Major Product Offerings

Table 26 CO.DON: Major Product Offerings

Table 27 Human Stem Cell Institute: Major Product Offerings

Table 28 MEDIPOST: Major Product Offerings

Table 29 NUVASIVE: Major Product Offerings

Table 30 NIPRO: Major Product Offerings

Table 31 Orchard Therapeutics: Major Product Offerings

Table 32 RMS Regenerative Medical System: Major Product Offerings

Table 33 Orthocell: Major Product Offerings

Table 34 Osiris Therapeutics: Major Product Offerings

Table 35 Sibino GeneTech: Major Product Offerings

Table 36 Shanghai Sunway Biotech: Major Product Offerings

Table 37 Takeda Pharmaceutical Company: Major Product Offerings

Table 38 Terumo: Major Product Offerings

Table 39 Vericel: Major Product Offerings

Table 40 Cell & Gene Therapy Market by Geography 2020?2026 (\$ million)

Table 41 Cell& Gene Therapy Market by Geography 2020?2026 (%)

Table 42 Cell & Gene Therapy Market by Product 2020?2026 (\$ million)

Table 43 Cell& Gene Therapy Market by Product 2020?2026 (%)

Table 44 Cell & Gene Therapy Market by End-User 2020?2026 (\$ million)

Table 45 Cell& Gene Therapy Market by End-User 2020?2026 (%)

Table 46 Cell & Gene Therapy Market by Application 2020?2026 (\$ million)

Table 47 Cell& Gene Therapy Market by Application 2020?2026 (%)

## I would like to order

Product name: Europe Cell and Gene Therapy Market - Industry Outlook and Forecast 2021-2026

Product link: <https://marketpublishers.com/r/EFE290639D36EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EFE290639D36EN.html>